35946006_l (1).jpg

Amarex Taiwan to Keynote at BioAsia-Taiwan 2020 Online + Live | July 22-26

On Friday, July 24, President & CEO of Amarex Taiwan, Dr. Kazem Kazempour, will keynote at Workshop 2 on the topic of Clinical Trials for Advances Therapies.

28 May 2020
accepted.jpg
25 June 2020
------------_KK_edited.jpg

Free Webinar: Points to Consider - Trial Design in General & Adaptive Trials in Particular | June 16, 2020

This webinar will be presented by Amarex President and CEO, Dr. Kazem Kazempour. He will address aspects of before study and after study clinical trial design, focusing specifically on the advantages and disadvantages of adapting a clinical trial.

Register for this webinar here.

05 June 2020
69639433_l (2).jpeg

Amarex Client Now Enrolling Patients for a Blood Filtration Device Study Treating COVID-19 Patients Experiencing Septic Shock

In April, Amarex Clinical Research, LLC, an NSF International company, achieved rapid, supplemental Investigation Device Exemption (IDE) approval from the U.S. FDA, on behalf of its client, to treat COVID-19 patients experiencing septic shock under an already underway Phase III clinical trial of a blood filtration device.  

02 June 2020

As a full-service, international CRO, Amarex Clinical Research has extensive experience successfully performing clinical studies across all phases of research and discovery, development, validation and approval.​​​

Recommended by the people who matter most: our clients.

 

Chief Medical Officer 

A Maryland Biotech Company

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.

        

             5/5

Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.

        

             5/5

VP, Clinical Development

A Canadian Device Company

To this focused and hard-working team: I count myself lucky to work with such caring individuals.Thanks for being some of the most interesting and high performing people I've ever worked with.

        

             5/5

AMAREX_NSF_1C.png
  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon

           

           © 2020 Amarex Clinical Research, LLC, an NSF International company. All rights reserved.                                                                                                                                                                                                  Top of Page 

Contact     Privacy Policy     Clinical Site Registration     WebView

NSF Mark_100x100.jpg